perifosine

12/15/2007 - "Perifosine induced significant reduction in WM tumor growth in vivo in a subcutaneous xenograft model through inhibition of Akt phosphorylation and downstream targets. "
01/01/2020 - "In this study, we investigated the role of external pH in control of cytotoxicity of perifosine, the Akt signaling pathway inhibitor, to CRC cells using 2D and 3D tumor models. "
12/01/2018 - "Our study extends our understanding of the spectrum of novel targets that are differentially ubiquitinated after perifosine treatment of NB tumor cells."
12/01/2017 - "Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations."
01/15/2017 - "The oral AKT inhibitor perifosine showed tolerable toxicity in adults and in our phase I trial in children with solid tumors (clinicaltrials.gov NCT00776867). "

11/01/2017 - "Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma."
01/15/2017 - "A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma."
02/14/2020 - "The allosteric pan-AKT inhibitor perifosine had promising in vitro and in vivo activity in combination with conventional cytotoxic drugs in MYCN-amplified neuroblastoma cells. "
01/01/2012 - "Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine."
01/01/2017 - "Perifosine, an Akt inhibitor, has been shown to be effective in controlling neuroblastoma tumor growth. "

01/01/2017 - "Herein, the association between therapeutic efficacy and putative proapoptotic activity of low-dose BVZ either alone or in combination with a specific inhibitor of AKT called perifosine (PRF), in a glioma model was investigated. "
08/15/2005 - "However, the efficacy of perifosine in human gliomas has not been established. "
05/01/2015 - "Perifosine, an orally bioavailable, synthetic alkylphospholipid and potent Akt inhibitor, has demonstrated activity in some preclinical models, but absent activity in a genetically engineered mouse model of pontine glioma. "
03/15/2010 - "Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma."
06/01/2006 - "Thus, in vitro and in vivo data indicate that the perifosine-mediated decrease in Akt activity does not enhance the radiosensitivity of three genetically disparate glioma cell lines. "

07/01/2020 - "Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. "
07/01/2006 - "In addition, perifosine, an inhibitor of Akt activation that exhibits substantial antimyeloma activity in preclinical models, is being examined in relapsed multiple myeloma. "
05/15/2006 - "Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells."
07/01/2007 - "Perifosine is a novel alkyl-lysophospholipid that can induce apoptosis in multiple myeloma (MM) tumor cells, both in vitro and in vivo. "
01/01/2012 - "However, given the recent encouraging early-phase combination therapy results in adults with multiple myeloma and colorectal carcinoma, rational perifosine-containing combination regimens hold promise for neuroblastoma therapy. "

10/01/2013 - "Perifosine has the potential to play a role in the treatment of leukemias in the future. "
10/01/2013 - "In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. "
01/01/2008 - "Perifosine was tested on THP-1 and MV 4-11 cell lines, as well as primary leukemia cells. "
10/01/2013 - "The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. "
06/01/2008 - "The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism."